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ARTICLE
Somatic mutagenesis in satellite cells associates
with human skeletal muscle aging
Irene Franco 1, Anna Johansson2, Karl Olsson3, Peter Vrtačnik1, Pär Lundin1,4, Hafdis T. Helgadottir1,
Malin Larsson5, Gwladys Revêchon1, Carla Bosia6,7, Andrea Pagnani 6,7, Paolo Provero8,9,
Thomas Gustafsson3, Helene Fischer3 & Maria Eriksson1
Human aging is associated with a decline in skeletal muscle (SkM) function and a reduction
in the number and activity of satellite cells (SCs), the resident stem cells. To study the
connection between SC aging and muscle impairment, we analyze the whole genome of
single SC clones of the leg muscle vastus lateralis from healthy individuals of different ages
(21–78 years). We find an accumulation rate of 13 somatic mutations per genome per year,
consistent with proliferation of SCs in the healthy adult muscle. SkM-expressed genes are
protected from mutations, but aging results in an increase in mutations in exons and
promoters, targeting genes involved in SC activity and muscle function. In agreement with SC
mutations affecting the whole tissue, we detect a missense mutation in a SC propagating
to the muscle. Our results suggest somatic mutagenesis in SCs as a driving force in the
age-related decline of SkM function.
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Satellite cells (SCs) are a heterogeneous population of stemand progenitor cells that have been demonstrated to play apivotal role in skeletal muscle (SkM) hypertrophy,
regeneration, and remodeling1,2. The SCs are normally kept in a
quiescent state and activated upon exposure to stimuli, such as
exercise or SkM injury. When committed to myogenic
differentiation, SCs proliferate further, fuse to existing SkM fibers,
and contribute new nuclei to the growing and regenerating
fibers3. Aged human SkMs show a decline in the number and
proliferative potential of the SCs4. As a consequence, a dysfunc-
tional SC compartment is envisaged as a major contributor to
age-related defects, including reduced capacity to respond to
hypertrophic stimuli such as exercise and impaired recovery from
muscle disuse and injury1,5,6. Furthermore, SCs have been shown
to contribute to differentiated fibers in non-injured muscles of
adult sedentary animals7,8. The basal turnover of nuclei in
adult fibers appears to be less crucial in the protection from
sarcopenia7, a progressive loss of SkM mass and function, which
culminates in a highly disabling condition affecting up to 29% of
the population aged 85 years9. Nonetheless, SCs play an essential
role in limiting the occurrence of fibrosis in the SkM of mice
affected by sarcopenia7 and their function in the human
pathology needs to be further characterized.
A well-known factor in the decline of stem cell function is the
loss of genome integrity10, for example, caused by the appearance
of somatic mutations11. These modifications of the genome range
from single-base changes (single-nucleotide variants (SNVs)) to
insertions or deletions of a few bases (indels) to chromosomal
rearrangements and occur during the whole life, starting from the
first division of the embryo. In contrast to germline variants,
somatic variants are not propagated to the whole individual but to
a subpopulation of cells in the body, with the final consequence
that adult human tissues are a mosaic of genetically different
cells12–14. Moreover, somatic mutation burden increases during a
lifetime15–18 as a result of accumulating errors occurring either
during cell division or because of environment-induced DNA
damage. At present, nothing is known about somatic mutation
burden in human SCs or SkM.
Here, we investigate the genetic changes that occur with aging
in the genome of human adult SCs and use the results to elucidate
mutational processes and SC replication rate occurring in vivo in
adult human muscles. We assess the functional effects of somatic
mutations on SC proliferation and differentiation and predict the
global consequence on muscle aging and sarcopenia. Our analyses
reveal an accumulation of 13 mutations per genome per year that
results in a 2–3-fold higher mutation load in active genes and
promoters in aged SCs. High mutation burden correlates with
defective SC function. Overall, our work points to the accumu-
lation of somatic mutations as an intrinsic factor contributing to
impaired muscle function with aging.
Results
Increased somatic mutation burden in aged SCs. We examined
the somatic genetic variation in SCs from the leg muscle vastus
lateralis of a group of young (21–24 years, n= 3) and old (64–78
years, n= 4) individuals by whole-genome sequencing (WGS).
Because the sequencing of clonal populations is an effective
strategy to study the genome of single cells19,20, freshly isolated
cells expressing the SC antigen CD56 were single cell plated and
cultured for 17–20 divisions prior to DNA extraction (Fig. 1a).
Even though the selection of a pure SC population from muscle
biopsies requires the use of multiple markers besides CD5621, the
combined effect of our isolation protocol (Supplementary Fig. 1a)
and culture conditions ensured the almost exclusive growth of
satellite cell clones (SCCs, 57/58 tested colonies, Supplementary
Table 1). Two to five SCCs/biopsy and the relative SkM and blood
bulk DNA were subjected to WGS with an average depth of 30×
(Supplementary Table 2). The SC origin of the sequenced clones
was tested with either a differentiation assay or quantitative PCR
(qPCR) for the expression of the SC markers Pax7, MyoD, and
myogenin. Twenty one out of 21 tested SCCs resulted positive
(Supplementary Table 2 and Supplementary Fig. 1b and c).
Next, we analyzed somatic mutations in 29 SCCs. The
identified somatic SNVs ranged between 209 and 1371 per SCC
(Fig. 1b). Considering a calculated false negative rate of 0.41
(Supplementary Table 3), the actual number of somatic mutations
per genome was estimated to range between 354 and 2323, which
is consistent with studies in clonally expanded cells from human
fibroblasts19,22 and stem cells from the intestine and liver16. The
pipeline for calling somatic variants was validated by analyzing
two technical WGS replicates and showed a 94% and 99%
validation rate of the somatic SNVs (Supplementary Table 4). In
addition, WGS-independent validations of exonic SNVs selected
from several clones (n= 16) showed a 100% validation rate
(Supplementary Table 5). Somatic indels ranged between 8 and
109 per SCC (Fig. 1b and Supplementary Tables 2 and 6), with a
validation rate of 84% and 98% in WGS of technical replicates
(Supplementary Table 1D).
The somatic variants showed an age-dependent accumulation
of mutations in the SC genomes (Fig. 1b; P= 1.47 × 10–4 for
SNVs and P= 2.77 × 10−3 for indels), with a mutation rate of
13.1 ± 2.7 SNVs per genome per year during adult life (Fig. 1c).
Somatic mutations have been suggested to arise in the quiescent
state13, but errors occurring during cell division are generally
considered the major source of mutations23,24. If we only
consider cell division-coupled mutations and use a mutation rate
of 2.5 SNVs per genome per cell division25,26, we can estimate a
number of cell divisions per year in SCs of 5.24.
Specific pattern of somatic mutations in adult SCs. To obtain
insight into the mutational processes occurring in SCs in vivo, we
analyzed the profile of somatic substitution types. The somatic
variant profile considerably differed from the germline spectrum
assessed in the blood and muscle bulk of the same individuals
(Supplementary Fig. 2a). In contrast, the mutational profiles of
young and old SCCs were similar (Supplementary Fig. 2b). The
substitution classification was further refined by including the 5ʹ
and 3ʹ sequence context of each mutated nucleotide to obtain 96
mutation classes. Following established methods16,27, we extrac-
ted 3 SC-specific signatures (Supplementary Fig. 3a) that repre-
sent the distinct mutation processes occurring during SC aging.
Principal component analysis (PCA) of extracted signatures for
our data and published data from human fibroblasts19 showed
separate clusters for the two distinct cell types. The pure cluster
including all 29 SSCs confirmed the SC origin for all clones,
including the 8 clones where no material was available for vali-
dation (Supplementary Fig. 3b). We also studied how previously
established signatures (cancer signatures: http://cancer.sanger.ac.
uk/cosmic/signatures) contributed to the SC mutation profiles
(Supplementary Fig. 4 and Fig. 1d–g). SCC mutations can be
principally attributed to signature 1, which is associated with the
deamination of 5-methylcytosine, signature 5 and signature 8
(Supplementary Fig. 2a and Fig. 1d). Signature 5 contributed the
highest number of mutations and the age-related increase was
higher for signature 5 than for the other signatures (Fig. 1f, g).
Interestingly, old SCCs presented a higher fraction of signature 5
mutations compared to young SCCs (Fig. 1e). This indicates that
signature 1 and 8 mutations steadily accumulated during a life-
time, while the accumulation rate of signature 5 specifically
increased between 20 and 70 years of age. Signature 18, which was
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previously associated with culture-induced somatic mutations16,
was almost absent in SCCs cultured with our standard protocol
but increased in a control subset of SCCs that underwent an
additional 50 days of in vitro expansion between the isolation and
single-cell plating (Supplementary Fig. 4b). The control sub-
set also presented a higher fraction of C>A conversions (Sup-
plementary Fig. 2b), which is consistent with culture-induced
mutation processes16. These results confirm that our strategy for
calling somatic variants efficiently excluded mutations that
occurred during in vitro culture.
Mutation accumulation in SkM-expressed exons and pro-
moters. We analyzed the somatic mutation distribution across
the genome. Plotting the variants according to either their
chromosome position (Supplementary Fig. 5a) or annotation
(Table 1) did not show a specific pattern or any age-related dif-
ferences other than the increased mutation burden associated
with age (Fig. 2a). However, in both young and old SCCs, the
mutation frequency was lower than expected in exons and reg-
ulatory regions (Fig. 2b, c). The under representation was more
pronounced in the exons expressed in the SkM than in all the
exons (P= 4.55×10−6) (Fig. 2b), consistent with a specific pro-
tection of functional regions. The protection extends to the
introns of the same genes (Supplementary Fig. 5b), suggesting
that it is due to the activity of the transcription-coupled repair.
Interestingly, mutation depletion in exons and regulatory regions
of young SCCs was stronger than in old SCCs (Fig. 2b, SkM-
expressed exons; and Fig. 2c, promoters), while introns were
equally protected from mutations in young and old SCCs (Sup-
plementary Fig. 5b). These results indicate that the regions of the
genome involved in the production of the proteome were
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Fig. 1 Age-related increase of somatic mutations in satellite cells. a Experimental strategy for somatic variant detection with whole-genome sequencing
(WGS). The reference sequence was obtained from the blood of every individual. The muscle vastus lateralis was sequenced as a population (muscle bulk)
or used to isolate CD56+ cells. These were either tested to verify the percentage of satellite cells or single cell plated and sequenced as a clonal population
(SCCs) in order to detect cell-specific somatic mutations. The satellite cell origin of sequenced SCCs was tested in all clones that produced a sufficient
number of cells (21/29) b Total number of somatic single-nucleotide variants (SNVs) and insertion/deletions (indels) per SCC normalized to the
percentage of autosomes covered by the sequencing. The linear fit of mutation numbers and age is shown. P-values are calculated using a robust
mixed model. Different colors correspond to the donors. c Average number of SNVs and indels accumulated per year by the SCCs according to the
linear fit shown in b. d Absolute contribution of signatures 1, 5, and 8 to the mutation catalogue of each SCC. e Average percentage of SNVs/total SNVs
for the most relevant signatures in young and old SCCs. *P < 0.05 two-sided t-test. f Linear fit of cancer signatures 1, 5, and 8 with the age of the
SCCs. P-values were calculated with a robust mixed model with Bonferroni correction for multiple testing of different signatures (n= 3). g Yearly
increase in the selected cancer signatures obtained by the linear fits in f was plotted as a proportion of the total number of SNVs/Gb accumulating every
year in the SCCs
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subjected to a specifically higher accumulation of mutations in
aged SCs. In addition, old SCCs showed a higher ratio of non-
synonymous (potentially impairing the function of the gene) over
synonymous (neutral) mutations (Fig. 2d), meaning a higher
number of potentially deleterious mutations compared to young
SCCs. Overall, these results point to a specific degeneration of
active genes and promoters with aging.
Somatic mutations in active genes during SC differentiation.
To obtain insight into the mutation load in specific genes ensuing
differentiation and proliferation in SCs, we mapped our muta-
tions to expression data generated by the FANTOM5 project28.
These data provide a map of the exons, promoters, and enhancers
that are active during the in vitro differentiation of myoblasts to
myotubes (Supplementary Fig. 6), a process that mimics in vivo
SC activation and fusion to differentiated fibers. We found that
old SCCs carried an average of 11.5, 2.25, and 7.37 mutations per
genome in the enhancers, promoters, and exons, respectively
(Fig. 3a). These values were 2.4-fold higher than those in young
SCCs. Notably, in the exons and promoters that were specifically
expressed upon exposure to differentiation stimuli, the increase
was more pronounced (fold increase 3.06 and 3.26 in exons and
promoters, respectively), indicating that the chances of impairing
the expression of a gene that is fundamental for SC differentiation
strongly increased with age.
Mutation load coincides with functional defects in old SCs. In
accordance with the possibility that somatic mutations impaired
the function of important genes for SC differentiation, the
number of SCCs able to differentiate into myotube structures
inversely correlated with the average number of mutations per
biopsy (Fig. 3b). We ruled out that the lack of myotube formation
was caused by the non-myogenic origin of the SCCs by assessing
the expression of MyoD in a subset of clones that did not respond
to the differentiation treatment (n= 14). In addition, the colony-
forming ability and long-lasting proliferative potential inversely
correlated with the average number of mutations per genome in
the SCs derived from the seven biopsies included in this study
(Fig. 3c), supporting the hypothesis that higher numbers of
mutations impaired cell proliferation.
Furthermore, we analyzed the proliferative capacity of
individual SCCs that underwent WGS. We noticed that the SCCs
that showed a higher fraction of senescent and un-proliferative
cells required longer times to reach the 30,000–100,000 cells that
are necessary for DNA extraction. Thus we used the time in
culture as a measure of healthy proliferation and investigated
whether the number of somatic mutations influenced this
parameter. No correlation was found for young SCCs (Fig. 3d),
which is consistent with the low mutation burden and the lack of
an effect on proliferation. In contrast, in the old SCCs the
proliferation time gradually increased with increased mutation
burden (Fig. 3d). In order to define a mutation threshold that old
SCCs can tolerate without showing proliferation defects, we
considered as a range of healthy proliferation the average ±
standard deviation of the days in culture of the young SCCs. The
intersection of the upper limit of this range with the linear
regression curve for old SCCs defined the mutation threshold and
was calculated as 1250 mutations per clone. Even though this
number is an underestimation, due to the stringent strategy for
calling somatic mutations that allowed a false negative rate of 0.41
(Supplementary Table 3), it was useful to define 2 subsets of old
SCCs. The population that carried < 1250 mutations was most
often placed in the range of normal proliferation (healthy old
SCCs, n= 9), while the majority of SCCs carrying > 1250
mutations showed abnormally long times in culture (diseased old
SCCs, n= 7). This is an indication that a high number of somatic
mutations affect the cell function. To understand the functional
effects of the mutations, the variants were given a lethality score
using CADD (Combined Annotation Dependent Depletion)29.
For every clone, a global effect of somatic mutations was defined
by the sum of CADD scores. The global CADD score
was calculated exclusively for the mutations that were harbored
in SC-expressed regions (according to FANTOM basal data
shown in Fig. 3a) (Fig. 3e) or including all the mutations of each
clone (Fig. 3f). Interestingly, the lethality score derived from
mutations in expressed regions was not significantly different for
healthy and diseased SCCs, while the score based on the complete
set of mutations was higher for diseased SCCs (Fig. 3f). All
together, these data provide a functional correlation between the
extent of the somatic mutation burden and the impairment of SC
activity.
Somatic mutations in muscle functional genes in old SCs. A
mutation burden that leaves the SC proliferative capacity intact
can also affect the muscle function by propagating to the genome
of the SC progeny (for example, differentiated fibers). Overall,
young clones presented an average of 5 exonic mutations per
SCC, compared to 11 in old SCCs (Fig. 4a). Hence, we explored
multiple sets of genes known to drive muscle changes, such as the
response to training and aging. Genes differentially expressed
after muscle training or participating in pathways involved in the
response to training5 (Fig. 4b and Supplementary Tables 7–9)
showed a 5–6-fold increased mutation load in aged compared to
young genomes. The same increase was observed for genes
differentially expressed with age. Higher mutation loads in these
genes increases the chances of defects in the muscle ability to
adapt to training and aging.
To determine whether the genes that are linked to muscle
diseases are more prone to somatic mutations, we mapped our
somatic SCC mutations to 173 genes that are known to harbor
pathogenic germline mutations (Fig. 4b). The results identified 4
genes (PLEC, SYNE2, TTN, and HSPG2) with somatic mutations
in exons, but the average number of mutations in the entire gene
set was not higher than expected when considering exons,
introns, and flanking regions (P= 0.1 and P= 0.45 for young and
Table 1 Average distribution of the annotated variants in
young and old SCCs
Young, 23 ± 0.9
years
Old, 71.2 ± 4
years
% of SNVs % of SNVs
Exona 0.9 ± 0.1 1.0 ± 0.1
3ʹ UTR 0.3 ± 0.1 0.3 ± 0.0
5ʹ UTR 0.0 ± 0.0 0.0 ± 0.0
Splice regionb 0.1 ± 0.0 0.1 ± 0.0
Intron 40.0 ± 0.4 39.5 ± 0.4
Upstream gene 6.3 ± 0.4 6.4 ± 0.3
Downstream gene 6.3 ± 0.4 6.7 ± 0.3
Regulatory regionc 2.6 ± 0.3 2.8 ± 0.2
Non-coding transcript exon 0.7 ± 0.1 0.6 ± 0.1
Intergenic 42.8 ± 0.6 42.6 ± 0.5
Percentage of mutations for each genomic feature reported as the mean ± standard error for
young and old SCCs. Variants were annotated with Variant Effector Predictor (VEP)
aCategories reflects Ensemble SO terms, except for exon: which includes stop gained, missense,
synonymous variants
bCategories reflects Ensemble SO terms, except for splice region: which includes splice region,
splice donor, and splice acceptor variants
cCategories reflects Ensemble SO terms, except for regulatory region: which includes regulatory
region and TF-binding site variants
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old SCCs, respectively. See Supplementary Table 10 and
Supplementary Note 1 for a complete list of mutations and
muscle disease genes).
Propagation of SC mutations in SkM. Finally, to analyze whe-
ther the potentially pathogenic somatic mutations that were
detected in the SCs were actually propagated to the SkM, we
designed assays for the rare event detection of a selection of
mutations (Supplementary Table 11). As expected, these muta-
tions were detected at an allele frequency close to 50%
(48.7–49.5%) in the SCC from which they were originally dis-
covered. Five out of the six variants were not detected in the
corresponding muscle biopsy, which is consistent with their
presence only in the sequenced SC or a fraction of cells below the
limit of detection of our assays (Fig. 4c, and Supplementary
Table 12). However, one variant, HSPG2 c.7825C>T; p.R2609W,
was present in 1.3% of the alleles of gDNA and 1.9% of the RNA
transcripts from the corresponding muscle biopsy (Fig. 4c and
Supplementary Fig. 7, Supplementary Table 12). The detected
mutation in SkM was likely not derived exclusively from the SCs
in the tissue, as the mutation was not identified in a population of
CD56+ cells or in additional SCCs from the donor (Supple-
mentary Table 12). Hence, this result supports the possibility that
somatic mutations detected in SCs are propagated to the adult
tissue, thereby increasing the negative effects of pathogenic
variants.
Discussion
Here, we have shown that SCs of the leg muscle vastus lateralis
accumulate somatic mutations during adulthood at a rate of 13
mutations per genome per year. Somatic mutation data have
been used as tracks on the genome to provide information
about the mutational processes and stem cell activities that
characterize the homeostasis of the uninjured muscle during
human aging.
First, we provided evidence that the somatic mutations detec-
ted with our strategy were true variants that occurred during
in vivo aging and not artifacts derived from either the WGS
sequencing or the in vitro cell culture. We tested the false positive
rate with multiple validation methods to quantify the amount of
errors due to the strategy for calling somatic variants. More than
94% of SNVs were validated, thus confirming our strategy for
discovering somatic variants. The detection of indels is technically
challenging30, and the analysis of somatic indels has been seldom
addressed. However, we were able to compile lists of somatic
indels with a validation rate of 84–94% and add these mutations
to the catalog of somatic mutations of adult SCs. To limit the
inclusion of SNVs and indels that had arisen during the culture of
the clone, our stringent filtering allowed only variants showing an
allele frequency between 0.4 and 0.6. In fact, variants that
occurred during culture would be present only in a subpopulation
of the cells. Unless mutations were non-neutral, a mutation must
have occurred during the first cell division to yield an allele
frequency of 0.25. To validate our strategy experimentally, we
analyzed the mutation pattern in a set of “positive control”
samples for culture-induced variants, e.g., SCCs obtained from
cells that stayed 50 days in culture before the cloning and
subsequently cultured as regular SCCs. These long-culture SCCs
showed features previously associated with cell culture-induced
mutations, such as a high fraction of C>A conversions and the
cancer signature 1816. Conversely, these features were almost
absent in regular clones, thus confirming that our strategy for
calling somatic variants efficiently excludes mutations that
occurred during in vitro culture and provides a faithful repre-
sentation of the genome of the SC at the moment of the isolation
from the muscle.
A drawback of the strategy was the high false negative rate
(0.41), mainly attributable to the stringent filtering on the allele
frequency, which allowed for the discovery of only a portion of
the true variants. This has implications for all our findings. For
example, we calculated an age-related increase of 13.1 somatic
mutations per genome per year and roughly estimated the rate of
cell divisions per year in the SCs to 5.24. Both numbers are
underestimated. However, these findings provide evidence in
favor of a basal proliferation of SCs in adult muscles not
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challenged by an injury or a disease. In particular, SCs are con-
sidered to stay mainly in a quiescent, non-proliferative state
under basal conditions and maintain a very low metabolic rate to
protect against DNA damage4. The proliferation of adult SCs in a
muscle that does not need to heal from a trauma is debated. Some
evidence has been provided in mice7,8, but a direct demonstration
in the human muscle was still lacking. The yearly mutation rate
calculated from our data points to a sustained proliferation rate.
However, we cannot determine whether the mutation accumu-
lation is due to a steady (basal) proliferation or due to a few bursts
occurring occasionally over decades. Moreover, we cannot
establish whether the proliferation rate is attributable to a small
fraction of dividing SCs, as was shown in the muscle of adult
mice31.
Beyond the quantitative data, an accurate analysis of the
mutation type, pattern, and location allowed the understanding of
mutation processes occurring in vivo in the adult human muscle.
Mutagenic events and their effects on the genome have been
collected in a catalog of mutational signatures (cancer signatures:
http://cancer.sanger.ac.uk/cosmic/signatures). Of these sig-
natures, 1 and 5 have previously been reported to increase with
age in cancer and non-cancer tissues15,16. These signatures were
the main signatures found in adult SCCs, together with signature
8. All three signatures progressively accumulated during aging.
However, signature 5 showed the highest accumulation rate and a
specific increase in adulthood compared to the period preceding
20 years of age. Unfortunately, the etiology of this signature is
unknown.
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The analysis of the genome distribution of somatic variants
indicated that several genetic regions harbor a number of muta-
tions that is lower than expected by random distribution. The
strongest protection from mutagenesis can be seen in the reg-
ulatory regions and in the SkM-expressed genes. Since these are
transcribed regions, a likely mechanism involved in their pro-
tection from mutations is the transcription-coupled repair, a
process in charge of repairing errors recognized by the
Polymerase-2 on the template DNA during transcription32.
Interestingly, both introns and exons are depleted of mutations,
and this is in line with the fact that they are actively transcribed.
However, only exons show a difference between young and old
SCCs, with the young exons being more efficiently protected from
mutations. This difference can also be observed in regulatory
regions and can be attributable to either a progressive accumu-
lation of mutations due to errors in the transcription-coupled
repair or an age-related decay of the mechanisms in charge of
specifically repairing the exons33. Another hypothesis is linked to
the selective pressure. A specific feature of exons is that they are
subjected to natural selection, e.g., non-functional alleles are
rarely found in a population of cells, because cells that carry a
defective gene are outcompeted by cells with functional alleles
and disappear. A measure of the selective pressure acting on
exons is the ratio of non-synonymous (potentially impairing the
function of the gene) over synonymous (neutral) mutations. In
agreement with a reduction of the selective pressure with aging,
old SCCs showed an increased non-synonymous to synonymous
mutation ratio compared to young SCCs. We hypothesize that the
high mutation burden makes the majority of old SCs unfit for
propagation and removes them from the environment. As a
consequence, the strongly reduced number of functional cells is
subjected to a milder selective pressure, in line with our data
showing a lower number of proliferating SCs isolated from old
muscles. Alternatively, the aged SC population may favor the
clonal dominance of SCs that carry advantageous mutations, as
seen for the hematopoietic and intestinal stem cells34.
A specific accumulation of mutations in transcribed regions
was also observed with a different approach, i.e., mapping somatic
mutations to the transcriptome of SCs obtained from the CAGE
(cap analysis gene expression) RNA seq data of the FANTOM
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project28. These data provide a map of the exons, promoters,
and enhancers that are active in cultured SCs and represent
a set of genes important for SC maintenance and
proliferation. Moreover, the regions expressed in response to
differentiating stimuli were registered, giving an indication of the
enhancers and genes important for SC differentiation and fusion
to myotubes. In all of these regions, old SCCs carried a number of
somatic mutations that was 2–3-fold higher compared to young
cells.
We wondered whether the higher mutation burden could cause
an impairment of the SC functions, e.g., proliferation and dif-
ferentiation. Alterations in the stem cell function during aging
have been ascribed to deregulation of both extrinsic and intrinsic
factors35. Extrinsic factors include molecules systemically deliv-
ered to the muscle or secreted by the local niche in the micro-
environment where the SCs reside. It has been demonstrated that
the SC environment changes over time and influences the SC self-
renewal and capacity for tissue regeneration36. On the other
hand, the age-related reduction in the number of SCs that are able
to repopulate the niche and differentiate into muscle fiberrs has
been demonstrated to also rely on cell-intrinsic factors, such as
the activation of signaling pathways37,38 and epigenetic
mechanisms39. With our model, we could explore how an
intrinsic factor, i.e., genetic alterations, affects the SC activity,
providing unique genome-wide data and direct assessment of the
ex vivo performance of SCs of different ages. First, we found a
negative correlation between the number of cells able to
proliferate and differentiate and the average mutation burden in
our biopsies. However, these correlations were based on data
from the SC populations. To analyze the specific proliferation
ability linked to each sequenced genome, we used data on the
time required to complete the clonal culture. We found that the
longer the time required for the colony to expand in culture, the
higher the number of somatic mutations in the genome of the
founder cell. This was true only for old SCCs, while no correlation
was found for young SCCs. Overall, these results suggest that
there is a threshold of mutations above which SC proliferation is
impaired. Young SCCs showed a mutation burden lower than this
threshold and proliferated normally. Conversely, old SCCs that
carried a number of mutations above the threshold generally
completed the clonal culture in abnormally long time. Similar
results were obtained when we attributed a lethality score to every
somatic mutation using CADD29. Old SCCs with normal pro-
liferative rate and old SCCs with impaired proliferative capacity
can be grouped and distinguished on the basis of the mutation
lethality score. Interestingly, the lethality score that was only
based on mutations in expressed regions could not distinguish
normally and abnormally proliferating old SCCs. Hence, the
effect of somatic mutations on cell fitness was dependent on the
whole mutation burden, not only on expressed regions. In sum-
mary, our data on the proliferation of sequenced SCCs support
the mutation burden as an important intrinsic factor regulating
SC function during aging.
Besides affecting the SC activity per se, somatic mutation
burden can be propagated to the mature tissue if SCs fuse to
differentiated fibers. Therefore, we assessed whether mutations
found in the SCs could be detected in the tissue of origin. To this
end, we tested six SNVs affecting exons and introns of muscle-
expressed genes and that showed high CADD scores. We found
that a missense SNV in the HSPG2 gene was present in 1.3% of
the alleles, which relates to 2.6% of the cells of the muscle of the
old individual from which the SC was derived. We also found that
this mutation was expressed at detectable levels. This HSPG2
variant has not previously been reported as pathogenic. However,
it is harbored in a conserved region (PhastCons= 1) and a
missense variant that changes the same amino acid (p.R2609Q)
was found in two different genetic diseases, dyssegmental
dysplasia (OMIM 224410) and Schwartz-Jampel syndrome
type 1 (OMIM 255800). Thus these results show that variants
found in single SCCs can be found at detectable levels in the
muscle and, if pathogenic, hamper the function of the
whole tissue. In line with this view, we used the somatic
variants found in SCCs to predict possible deleterious effects of
somatic mutations in aged SkMs. We analyzed the mutation load
in a number of gene sets that regulate muscle function such as
genes differentially expressed after muscle training, pathways
involved in the response to training, especially those that dete-
riorates with aging5, and genes differentially expressed with age.
Our results showed a mutation load increase of 5–6-fold with
increased age and suggested a link between the increased muta-
tion burden in old SCs and the defective response of aged muscles
to training.
In summary, we have shown that SCs of the vastus lateralis
muscle accumulate somatic mutations during life and provided
evidence that intrinsic factors, such as the loss of genome integ-
rity, contribute to aging of the SkM. Transcribed regions were
specifically affected, and the mutation burden correlated with the
capacity of SCs to proliferate and differentiate. Moreover, SCs
could propagate their genomic defects to differentiated fibers and
these defects might explain the decrease of muscle mass and
response to stimuli observed in sarcopenia. Additional studies are
required to assess similarities and differences in the age-related
accumulation of mutations in muscles other than the vastus
lateralis.
Methods
Clonal expansion of human SCs. Human SkM biopsies were obtained from
healthy volunteers according to Ethical Permit EPN 2015/847-31/1, the Stockholm
regional ethical review board. Informed consent was obtained from all donors. In
total, 50–100 mg of tissue from the muscle vastus lateralis were obtained using a
percutaneous needle biopsy technique40. A part of the tissue was frozen, while ~40
mg were freshly digested using 5 ml Trypl-LX in two rounds of 20 min incubations
at 37 °C, 5% CO2 and gentle agitation. Cells were pre-plated in the growth medium
in a 10-cm cell culture dish (Dulbecco’s modified Eagle’s medium (DMEM) F12
containing 1% ABAM and 20% fetal bovine serum (FBS)) for 30 min at 37 °C and
5% CO2. The non-attached cells were transferred to a 6-cm cell culture dish coated
with collagen I (5 µg/cm2 of Collagen I bovine protein, Gibco #A10644-01, fol-
lowing the “thin coating procedure”). The cells were left to adhere for 48 h. Then
the cells were detached and stained for CD56-PE (clone MY31, BD #347747,
dilution 1:200). Using a BD FACSAria™ Mu cell sorter (BD Biosciences, USA), the
cells were sorted based on their size and strong positivity for the antigen (see
Supplementary Fig. 1) and were single cell plated in at least one 96-multiwell
collagen-coated plate per biopsy. The cells were grown in a conditioned medium,
i.e., growth medium that was collected every 48 h from a culture of feeder SCs
(40–60% cell confluency), filtered through a 2-µm-wide pore filter and supple-
mented with FBS 1/10 of the volume. Colonies were counted after 14 days and
scored as positive when at least 16 cells were visible in the well. Approximately
21 days after plating, the colonies were moved to 24-multiwell plates. Depending
on the cell confluency, the colonies were then moved to six-multiwell plates. The
new plates were collagen coated but growth medium instead of conditioned
medium was provided. After an average of 52.9 ± 2.2 days in culture, the colonies
were confluent and used for the DNA extraction.
DNA extraction. DNA was extracted from the confluent wells of the six-multiwell
plate using the Gentra Puregen Kit, Qiagen. DNA was extracted from 30 mg of
muscle biopsy using the Gentra Puregen Kit, supplemented with a lysis buffer
containing Proteinase K as recommended by the supplier. DNA was extracted from
3ml of total blood that was collected in EDTA as recommended by the instructions
of the Gentra Puregen Blood Kit.
Whole-genome sequencing. The library preparation and sequencing were
carried out at NGI Sweden, Science for Life Laboratories, Stockholm, following
standard methods. For the SCCs, the library preparation was performed by a
semiautomatic NeoPrep station using the Illumina TruSeq Nano Kit (350 bp
average insert size) and 25 ng of DNA starting material. The libraries of the bulk
DNA samples were prepared with Illumina TruSeq PCR-free library preparations
(350 bp average insert size). Sequencing was performed on Illumina HiSeq X, PE
2×150 bp.
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SC purity of cultured CD56+ populations. The purity of the SC populations
isolated with our protocol was compared in different muscle biopsies by assessing
the transcript levels of the SC marker Pax7. In parallel with single-cell sorting,
CD56+ cells were sorted in a 24-well plate (Supplementary Table 1) and cultured
for 1 week to expand the population prior to RNA extraction. In addition, the
purity of the single-cell culture was tested by assessing the percentage of clones
derived from single-cell sorted cells that expressed the myocyte marker MyoD.
RNA levels were tested in those SCCs that were able to grow confluent in a 24-well
plate and 97.4% of clones (CES1 n= 3, CES6 n= 9, CES7 n= 14, and CES8 n=
13) were found positive. The relative expression of SC markers was measured using
the same calibrator, the CD56+ sorted population from CES3, expanded in culture
for 4 weeks (Pax7 expression characterized in Supplementary Fig. 1b). As negative
controls, a human fibroblast population and two clones from human subcutaneous
fat were used. Negative control samples never showed amplification of the SC
genes.
To further characterize the contaminant cell types that were present in our
CD56+ sorted populations, we expanded for 3 weeks and froze the unsorted
populations left from the original cell sorting of the CES biopsies. Thawed cells
were sorted for CD56 and fluorescence-activated cell sorting analysis was
performed to assess the percentage of cells expressing markers of SCs (Pax7
monoclonal, Hybridoma Bank, 10 μg/ml) and bone marrow-derived cells
(CD45-APC, clone HI30, BD Biosciences, USA). At least 7000 cells per sample
were counted. In addition, 5000 cells were cytospun on glass slides and
immunofluorescently labeled for the fibroblast marker TE-7 (CBL271,
Millipore, CA, USA). At least 300 cells per sample were counted. Thawed
cells sorted for CD56 were grown as single-cell clones with the same protocol
used in the original experiment and again the myogenic origin was tested by
MyoD expression. 100% of clones resulted positive (CES3= 4, CES6= 3,
CES7= 6, CES8= 6).
Verification of SC origin of the sequenced SCCs. Culture of SCCs from
CD56+ sorted cells does not guarantee the exclusive growth of SC colonies, due to
the presence of contaminant cells of myogenic and non-myogenic origin in the
CD56+ pool (see Supplementary Table 1). For this reason, the SC origin of the
sequenced SCCs was tested in a myotube-formation assay or by assessing the
expression of the SC markers Pax7, MyoD, and myogenin via qPCR. This test
could be performed for 21 of the 29 clones. The remaining eight clones showed a
scarce growth, and after DNA extraction, no cells were available for additional
tests.
Cell-culture assays. Proliferation assays were performed on the seven biopsies
included in the study (Supplementary Table 1). For every biopsy, at least 96 SCs
were plated as single cells (CES1, CES7, and CES8: N= 96; CES2, CES3, CES4, and
CES6: N= 144). After 2 weeks in culture, the percentage of cells able to form a
colony of at least 16 cells was scored (colony-forming SCs). SCs that were able to
grow up to 30,000–100,000 cells (confluent well of six-well plate) were scored
positive for long-lasting proliferative potential independent of the time in culture.
The differentiation assay was performed on confluent cells, by replacing growing
medium with differentiating medium (DMEM-F12, 1% FBS) for 5 days. The clones
were scored for the presence of visible myotubular structures and the RNA was
extracted to verify the myogenic origin. For this assay, the original plating of the
single-cell clones was used for biopsies CES1 n= 37, CES2 n= 39, and CES4 n=
29. For biopsies CES3, CES6, CES7, and CES8, the frozen expanded populations of
unsorted cells were thawed and grown for 1 week, than sorted for CD56, single cell
plated, and grown to confluency in 24-well plates (CES3 n= 21, CES6 n= 37,
CES7 n= 24, and CES8 n= 28 SCCs).
Long-culture SCCs. Freshly isolated SCs from a young individual
(Supplementary Table 1) were expanded in culture for 50 days using growth
medium (DMEM F12 containing 1% ABAM and 20% FBS), then the SCs were
single cell plated and cultured according to our protocol for clonal expansion of
SCs from human SkMs. The clones and blood bulk DNA from the donor were
sequenced, and the somatic variants were analyzed as a control for the in vitro-
induced mutations.
Somatic variant calling. Raw reads were aligned to the human reference genome
(GRCh37/hg19 assembly version), using bwa mem 0.7.1241. Samtools 0.1.1942
was used for alignment sorting and indexing, and qualimap v2.243 for the
alignment quality-control statistics. The raw alignments were then processed
using the GATK best practice44 with version 3.3 of the GATK software suite.
GATK RealignerTargetCreator and IndelRealigner were used to realign around
indels, Picard MarkDuplicates 1.120 to mark duplicates, and GATK Base-
Recalibrator to recalibrate base quality scores. Finally, genomic VCF files were
created using the GATK HaplotypeCaller 3.3. Reference files came from the
GATK 2.8 resource bundle and steps were coordinated using Piper v1.4.0 (www.
github.com/NationalGenomicsInfrastructure/piper).
To identify somatic variants, a specific pipeline was developed. For each SCC,
the union of variants called with HaplotypeCaller (GATK)45, MuTect2 (GATK
3.5.0), and FermiKit version r17846 were subjected to further filtering steps. First,
the variants present in any of the SCCs were gathered in a comprehensive
list of interesting positions, which was specific to each individual. For every clone
of the individual, the read distribution of the interesting positions was derived
from the .bam files and matched to the relative blood bulk. Variants were called
when all of the following criteria were met: the read fraction supporting the
alternative allele fell in the desired region (0.4–0.6), the read fraction in the blood
was low (alternative < 0.1), and the coverage in both the clone and blood was at
least 15×. Chromosomes X and Y were excluded from the analyses. Additional
quality filters were applied as follows: the reads supporting the variants were on
both strands, the maximum coverage was 1000×, and the variants that were
located in problematic regions47,48 and those detected in more than one
individual were removed. The variants were annotated using the Ensembl Variant
Effector Predictor from ref. 49. Filtered somatic mutations in young, old, and
long-term cultured human SC identified in the study are available in
Supplementary Data 1–3.
Estimate of false negative rate. The estimate of false negative rate was done by
counting how often heterozygous SNVs were detected in the clone bam file with
an allele frequency that allows our pipeline to classify it as have occurred in vivo,
i.e., 0.4–0.6 allele frequency. First, a set of high-confidence SNVs for which the
individual was germline heterozygote (bulk and blood) and present with an allele
frequency > 0.3 in the SweGen population was generated. Second, the germline
heterozygote SNVs with a clone depth minimum of 15× were selected. Third, the
number of SNVs that were detected in the clone bam file by GATK and/or
Fermikit and/or MuTect2 were collected. Finally, the number of SNVs with allele
frequency 0.4–0.6 were counted using the Samtools mpileup. Similarly, we esti-
mated how often homozygous SNVs are detected with minor allele frequency
under 0.1 in blood. High-confident homozygous SNPs were created in the same
way as above, and Samtools mpileup was used to count the number of SNVs with
allele frequency below 0.1 in the blood. To yield the false negative rate, the
positive prediction rate (e.g., the fraction of SNVs with allele frequency 0.4–0.6 of
the total number of SNVs and correct called homozygous SNVs) was subtracted
from 1.
Variant validation. The variant validation was performed on technical replicates
of WGS. Clone P2703_113 was sequenced twice with independent library
preparations. Clone P2703_116 was split into 2 wells during the cell culture (1000
cell-stage) and resulted in 2 independently grown clones (P2703_116 and
P2703_119) derived from the same ancestor cell. The DNA was extracted and
sequenced independently, but clone P2703_119 was not included in the study.
Variants were called in clones P2703_113 and P2703_116 (discovery set)
according to our somatic variant calling pipeline. Called variants that had a
minimum coverage of 10× in both the discovery and the validation sets were used
for the validation. In total, 798 SNVs and 82 indels of clone P2703_113 and 1140
SNVs and 66 indels of clone P2703_116 were tested. Variants were considered
validated when at least three reads supporting the alternative alleles were present
in the validation set. As a control for the background signal, we validated the
variants in unrelated clones, e.g., clones derived from a different founder cell
obtained from the same or a different biopsy. For a WGS-independent validation,
we used Agena genotyping (sequenom maldi-tof technology), which was per-
formed at the Mutation Analysis Facility at the Karolinska Institute. The SNVs
predicted to have high-impact consequences on the encoded protein were
selected from all clones and tested when assays were designable (n= 11) in all
clone, muscle bulk, and blood bulk DNA included in the study. The variants were
considered validated when the expected genotype was found in the clone from
which the SNV was discovered, and the reference allele was found in all the other
samples, including the relative blood bulk sample. In addition, six SNVs selected
based on their impact on muscle physiology were validated by digital droplet PCR
(ddPCR; Bio-Rad) in the clone from which the SNV was discovered and the
relative bulk samples.
RNA extraction and qPCR. RNA was extracted from muscle biopsies using Tri-
Zol® Reagent (Invitrogen) and from cultured cells using the RNeasy Mini Kit
(Qiagen), according to the manufacturers' instructions. cDNA synthesis was per-
formed using random hexamers and SuperScript Reverse Transcriptase (Invitro-
gen). Quantitative reverse transcriptase PCR (RT-PCR) was performed using
Taqman qPCR reagents and an ABI7500 fast system sequencing detection
instrument (Applied Biosystems). Primers and probes were assays on demand from
Applied Biosystem (Pax7 Hs00242962_m1; MyoD1, Hs00159528_m1; myogenin
Hs01072232_m1) and the normalizer gene was glyceraldehyde 3-phosphate
dehydrogenase (#4352665, Applied Biosystems).
Digital droplet PCR. The rare event detection (RED) analysis was performed using
the QX200 ddPCR system (Bio-Rad, Hercules, CA, USA). DdPCR assays (Bio-Rad,
Hercules, CA, USA) were designed to detect six SNVs, namely, HSPG2 (chr1:
22174499G>A, assay id: dHsaMDS988410713), TTN (chr2: 179560728G>A, assay
id: dHsaMDS896792909), FN1 (chr2: 216272892C>T, assay id:
dHsaMDS668887829), FNDC1 (chr6: 159682281T>A, assay id:
dHsaMDS711365861), RAP1GDS1 (chr4: 99338610C>T, assay id:
NATURE COMMUNICATIONS | DOI: 10.1038/s41467-018-03244-6 ARTICLE
NATURE COMMUNICATIONS |  (2018) 9:800 | DOI: 10.1038/s41467-018-03244-6 |www.nature.com/naturecommunications 9
dHsaMDS467491822), and CACNA2D2 (chr3: 50426879C>T, assay id:
dHsaMDS892017893). The PCR reactions were performed using 2× ddPCR
Supermix for Probes (no dUTP) (Bio-Rad), 20× ddPCR mut assays (FAM/HEX
labeled) (Bio-Rad), 5 U of HindIII restriction enzyme (New England BioLabs,
Ipswich, MA, USA), and template DNA and ran according to the manufacturer’s
instructions. gBlocks gene fragments (IDT, Coralville, IA, USA), carrying one of
the six SNVs each, were spiked into the human DNA sample and used for testing
the ddPCR assays and optimizing the PCR thermal cycling conditions prior to the
analysis of the samples. Approximately 30 ng of sample DNA per well were used in
the analysis, except for the case of DNA from the additional clones from individual
CES6 for which only 5 ng per well were used due to the low amount of available
DNA. All samples were run in two or more replicate wells, and the data were
merged from all the replicate wells to calculate the fractional abundances of the
mutant alleles. Sample data were only accepted when falling within established
detection parameters, which include a minimum of 3 positive droplets per sample
and 10,000 accepted droplets per well.
Owing to the exonic position of the HSPG2 and FN1 mutations, the same assay
could be used with both DNA and cDNA. To perform the RED on the cDNA
samples, 1 μg of RNA was treated with DNase using RQ1 RNase-Free DNase
(Promega, Madison, WI, USA) prior to the cDNA synthesis via the SuperScript
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA, USA), which
was performed according to the manufacturer’s instructions. The RED was
performed as described for DNA. Approximately 50 ng of sample cDNA per well
were used for the analysis, except for the case of cDNA from the SC population
from a control individual, for which the amount of cDNA had to be reduced to 7.5
ng per wall to prevent overloading of the assay.
Mutational signatures. All analyses of base substitutions (Supplementary Fig. 2b)
and mutational signatures (Fig. 1 and Supplementary Figs. 3 and 4) were carried
out using the R-package MutationalPatterns16,50 following the creators’ instruc-
tions. In brief, base substitution patterns of the somatic mutations detected in SCCs
were analyzed and visualized with MutationalPatterns using the reference genome
set to “BSgenome.Hsapiens.UCSC.hg19”. Using the function “mut_matrix”, the
relative contribution of the six single base substitution subtypes: C:G>A:T, C:G>G:
C, C:G>T:A, T:A>A:T, T:A>C:G, and T:A>G:C, was refined by including the
sequence context 5ʹ and 3ʹ of each mutated base to obtain a 96 trinucleotide
substitution count matrix. We performed de novo extraction of mutational sig-
natures from the SCC mutations using non-negative matrix factorization51 by
applying the function “extract_signatures” to our data. We used the 96 trinu-
cleotide substitution count matrices for all SCCs (n= 29) as input and specified
that three signatures should be extracted (rank= 3). The contribution of the 96
possible trinucleotide substitution types to the extracted signatures was visualized
using the function “plot_96_profile” (Supplementary Fig. 1f). The relative con-
tribution of the extracted signatures to the mutational catalog was used for the PCA
(Supplementary Fig. 1g). We used the function “fit_to_signatures” to assess how
well the mutational catalog of our SCCs can be expressed as a combination of the
previously identified cancer signatures (http://cancer.sanger.ac.uk/cosmic/
signatures). Whole-genome data were then expressed as SNVs/Gbase/SCC and
replotted (Fig. 1f). For each signature, the number of mutations per SCC was
plotted and the linear fit with donor age was used to calculate the year increase
(Fig. 1g). Analyses in R were done using RStudio Version 0.98.1025. Signature data
were analyzed using the following pipeline to obtain principal components of the
29 sequenced SSCs and previously published sequence data from human fibro-
blasts27: (i) data were normalized on a per clone base; (ii) normalized data were
transformed into principal components (NB: these principal components are the
ones shown in the plots); (iii) 100,000 permutations of k-means clustering algo-
rithm (with k= 2) have been performed on data restricted to the first three
principal components. This pipeline has been implemented using MATLAB, and
all programs have been run with default parameters.
Genomic distribution of mutations. The distribution of somatic mutations across
the human genome (Supplementary Fig. 5a) was visualized using the function
“plot_rainfall” of the R-package MutationalPatterns16,50. The observed and
expected numbers of mutations in the different genomic regions (Fig. 2b, c) were
analyzed using the function “genomic_distribution”. Input data were the somatic
mutations detected in SCCs, genomic regions with enough sequencing depth (15×)
in every SCC, and the genomic regions that should be tested for enrichment or
depletion of somatic mutations, all represented as GRanges objects52. Regulatory
regions were extracted from Ensembl using the BioMart database “regulation”,
dataset “hsapiens_regulatory_feature” and GRCh “37”. Promoter regions were
extracted using the filter “regulatory_feature_type_name” set to “Promoter”. Pro-
moter flanking regions were extracted using the filter “regulatory_feature_-
type_name” set to “Promoter Flanking Region”. Open chromatin regions were
extracted using the filter “regulatory_feature_type_name” set to “Open chromatin”.
Transcription factor (TF)-binding regions were extracted using the filter “reg-
ulatory_feature_type_name” set to “TF binding site”. To test for significant
depletion or enrichment of somatic mutations in genomic regions, we used the
function “enrichment_depletion_test” with the observed and expected number of
mutations in the genomic regions as input. The results were visualized using the
fuction “plot_enrichment_depletion”, with the significance test data as input. Exon
data were extracted from Ensembl using the BioMart database “ensembl”, dataset
“hsapiens_gene_ensembl” and GRCh “37”. Information on genes that were
detected or not detected on RNA level in the SkM was extracted from the
human protein atlas (http://proteinatlas.com). A list of genes detected in the
SkM was obtained by concatenating the results from the search terms
“tissue_specificity_rna:skeletal muscle;elevated AND sort_by:tissue specific score”,
“tissue_specificity_rna:any;expressed in all”, and “tissue_specificity_rna:skeletal
muscle;mixed” at http://proteinatlas.org. A list of genes not detected in
the SkM was generated by the search term “tissue_specificity_rna:skeletal muscle;
not detected” at http://proteinatlas.org. Based on Ensembl ID, we selected the
subsets of all exons extracted from the BioMart database “ensemble” that were
present in the list of genes detected in the SkM or in the list of genes not detected in
the SkM.
The distribution of mutations in 173 muscle disease genes was tested against a
null model as follows. SCCs were assigned to the young (n= 13) and old (n= 16)
groups and all genes harboring a mutation were registered for each group. The total
number of mutations with encode annotation to a gene (e.g., harbored in extended
gene regions including exons, introns, and 5 kb upstream and downstream of each
gene) was counted for each group. We sampled 104 times the same number of
exons from the list of all exons (“hsapiens_gene_ensembl” previously described)
proportionally to their length and then computed how many extracted extended
gene regions were present in the list of muscle disease genes. P-value and Z-score
were then evaluated by comparing the empirical number of mutations with the
distribution of the null-models using one-sided t-test. Full gene length was
obtained from Gencode, release 19.
Mutation load in specific genomic regions and gene sets. For the analysis of
genes, promoters and enhancers actively expressed during myoblast to myotube
differentiation (Fig. 3a) data were downloaded from the FANTOM5 project at
http://fantom.gsc.riken.jp/data/ (human_permissive_enhancer-
s_phase_1_and_2_expression_tpm_matrix.txt.gz and hg19.cage_peak_pha-
se1and2combined_counts_ann.osc.txt.gz)53. Expression data were available at 8
different time points during the myoblast to myotube differentiation (CNhs13847-
14585): day 00 (basal), day 01, 02, 03, 04, 06, 08, 10, and 12 upon exposure to
differentiation stimuli. Exploiting different time points, two expression sets, “basal”
and “upon differentiation”, were created. “Basal” corresponds to transcribed
regions on day 00. For “upon differentiation”, transcribed regions at all time points
were intersected with expressed regions on day 00 and the non-overlapping portion
of transcribed regions at all time points was taken. To determine actively tran-
scribed promoters and enhancers, we determined an arbitrary threshold based on
surveyed region size (see Supplementary Fig. 8). For enhancers, all regions with an
expression score ≥1 were included and the considered regions were enlarged
+/−100 bp. For promoters, all regions with an expression score ≥30 were included
and the considered regions were enlarged of an asymmetric window of 860 bp
upstream and 100 bp downstream. For exons, gene names were derived from
expressed regions reported in the promoter list and the exonic regions of
each gene were derived from “hsapiens_gene_ensembl” previously described.
Three different donor replicates were used and regions transcribed with intensity
equal or above the threshold in at least one replicate were included. Size of
surveyed regions was 4525728 and 32409968 bp for enhancers in “basal” and “upon
differentiation”, respectively, 5335985 and 3903736 for promoters, and 17542615
and 11123995 for exons. Somatic SNVs and indels were annotated to the described
regions and quantified for every SCC and the average of mutations in young and
old SCCs was reported. When enhancer and promoter regions overlapped,
mutations were attributed to either one based on manual investigation of the
region.
For the analysis of the numbers of mutations in gene sets involved in muscle
function (Fig. 4b), genes were derived as described in Supplementary Tables 7 to 9.
Lists of exonic mutations in young and old clones were screened and every
mutation that was annotated with a gene name included in the gene set was scored.
The average number of mutations per gene was calculated by dividing the number
of mutations in the gene set by the number of tested SCC (young n= 13, old n=
16) and the number of genes in the gene set.
Statistical analyses. Unless otherwise indicated, P-values were calculated using
two-tailed distribution, two-sample unequal variance Student’s t-tests, with sig-
nificance defined as P < 0.05 (*P < 0.05, **P < 0.01, ***P < 0.001). The results are
presented as the mean ± standard error of the mean (SEM). All calculations were
performed using the GraphPad Prism software. The linear fits between mutation
numbers and age shown in Fig. 1 were obtained using a robust mixed model where
the dependent variable is the number of mutations or a given mutational signature,
the fixed effect is age, and the random effect is the individual. Bonferroni correction
for the number of tested signatures was applied in Fig. 1f. Analyses were performed
in R.
Data availability. The sequence data that support the findings of this study are
available within the article and its Supplementary Information (Supplementary
Data 1–3). Raw sequence data are only available from the corresponding author
upon request and will be made available to research projects that fulfill the
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informed consent, owing to regulations pertaining to the authors' deposition of
these data in public repositories.
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